title: [Perioperative anticoagulation management for prosthetic heart valves].
abstract: OBJECTIVE
  The practices and the guidelines over the perioperative management of the anticoagulation of patients with cardiac valves prothesis are the object of no consensual attitude. The thrombotic risk over the time is well known. It depends of the type or the location on the valve, of their associations and the age of the patient. In the perioperative period, the antithrombotic treatment must be interrupted according to the surgical haemorrhagic risk.
  
  
  METHODS
  Short review.
  
  
  RESULTS
  Only patients, without associated risk factor, carriers of bioprosthesis from more than 3 months, can be maintained only under antiplatelets agents. In others situations, the caution imposes a bridge of anticoagulants from 48 to 72 hours with unfractionated heparin (subcutaneous at home, intravenous at the hospital). Low molecular weight heparin has no commercial authorization in this indication. The resumption of the anticoagulation by unfractionated heparin in postoperative period must be the most premature possible after the decrease of the surgical bleeding. The relay by vitamin K antagonists has to be made over 48 to 72 hours. Within the framework of the urgency, the surgical haemorrhagic risk is weak for an INR <1.5. According to the urgency of the surgery, a treatment by vitamin K (if the delay is over 12 hours) or by prothrombinic complex allows to correct this INR. The identification of thrombotic complications requires a particular attention. In the postoperative period, as soon as there is suspicion of thrombosis, clinical manifestations must be consolidated by the practice of a transoesophageal echography, which only confirm the diagnosis.
authors.affiliation: Fédération d'anesthésie-réanimation chirurgicale, CHU de Bordeaux, groupe hospitalier Sud, 33604 Pessac cedex, France.
authors.forename: K
authors.initials: K
authors.lastname: Nouette
authors.forename: P
authors.initials: P
authors.lastname: Richebé
authors.forename: J
authors.initials: J
authors.lastname: Calderon
authors.forename: C
authors.initials: C
authors.lastname: Mouton
authors.forename: G
authors.initials: G
authors.lastname: Janvier
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D007431:Intraoperative Complications / Q000097:blood / Q000517:prevention & control*; D011300:Preoperative Care; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants